These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11757694)

  • 1. The future of monoclonal antibody engineering.
    Renner C; Hartmann F; Pfreundschuh M
    Ann Hematol; 2001; 80 Suppl 3():B127-9. PubMed ID: 11757694
    [No Abstract]   [Full Text] [Related]  

  • 2. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

  • 3. Generation of humanized monoclonal antibodies by 'best fit' framework selection and recombinant polymerase chain reaction.
    Lewis AP; Crowe JS
    Year Immunol; 1993; 7():110-8. PubMed ID: 8372500
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural correspondences between mouse and human immunoglobulin VH genes. Application to the humanization of mouse monoclonal antibodies.
    Poul MA; Lefranc MP
    Ann N Y Acad Sci; 1995 Sep; 764():359-61. PubMed ID: 7486546
    [No Abstract]   [Full Text] [Related]  

  • 5. Chimeric antibodies.
    Billetta R; Lobuglio AF
    Int Rev Immunol; 1993; 10(2-3):165-76. PubMed ID: 8360583
    [No Abstract]   [Full Text] [Related]  

  • 6. Self-assembly of antibodies by chemical induction.
    Li Q; Hapka D; Chen H; Vallera DA; Wagner CR
    Angew Chem Int Ed Engl; 2008; 47(52):10179-82. PubMed ID: 19025747
    [No Abstract]   [Full Text] [Related]  

  • 7. [Transgenesis and humanization of murine antibodies].
    Cogné M; Duchez S; Pascal V
    Med Sci (Paris); 2009 Dec; 25(12):1149-54. PubMed ID: 20035696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic antibodies and antibody fusion proteins.
    Rohrbach P; Broders O; Toleikis L; Dübel S
    Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
    [No Abstract]   [Full Text] [Related]  

  • 9. The construction of a mouse/human chimeric antibody against human breast cancer cells.
    Meulemans E; Vandevyver C; Volckaert G; Raus J
    Year Immunol; 1993; 7():131-6. PubMed ID: 8372502
    [No Abstract]   [Full Text] [Related]  

  • 10. [Development of recombinant scFv-antibodies against diphtheria toxin using phage display system].
    Oleĭnik ES; Kaberniuk AA; Burkaleva DA; Romaniuk SI; Kolibo DV; Shepeliakovskaia AO; Laman AG; Komisarenko SV
    Ukr Biokhim Zh (1999); 2007; 79(5):91-7. PubMed ID: 18357781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering antibodies for the clinic.
    Holliger P; Bohlen H
    Cancer Metastasis Rev; 1999; 18(4):411-9. PubMed ID: 10855784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
    Heng BC; Cao T
    Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phage display technology in antibody engineering: design of phagemid vectors and in vitro maturation systems.
    Söderlind E; Simonsson AC; Borrebaeck CA
    Immunol Rev; 1992 Dec; 130():109-24. PubMed ID: 1286867
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
    Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
    J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity.
    Nikula TK; Bocchia M; Curcio MJ; Sgouros G; Ma Y; Finn RD; Scheinberg DA
    Mol Immunol; 1995 Aug; 32(12):865-72. PubMed ID: 7565813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of a humanised single chain Fv (Scfv) derived from the monoclonal Eric-1 recognising the human neural cell adhesion molecule.
    Whittington HA; Hancock J; Kemshead JT
    Med Pediatr Oncol; 2001 Jan; 36(1):243-6. PubMed ID: 11464896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a new intrabody directed against the N-terminal region of human p53.
    Cohen PA; Mani JC; Lane DP
    Oncogene; 1998 Nov; 17(19):2445-56. PubMed ID: 9824155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse/human chimeric IgE antibodies directed to the house dust mite allergen Der p 2.
    Schuurman J; Lourens TE; Perdok GJ; Parren PW; Aalberse RC
    Int Arch Allergy Immunol; 1995; 107(1-3):465-6. PubMed ID: 7613217
    [No Abstract]   [Full Text] [Related]  

  • 20. Radioimmunotherapy with engineered antibodies.
    Russeva MG; Adams GP
    Expert Opin Biol Ther; 2004 Feb; 4(2):217-31. PubMed ID: 14998779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.